microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production-Reference-Cited by-同舟云学术

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production

Published:2020-12-03 Issue:23 Volume:5 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Dong Jianjie,He Ming,Li Jie,Pessentheiner Ariane,Wang Chen,Zhang Jin,Sun Yameng,Wang Wei-Ting,Zhang Yuqing,Liu Junhui,Wang Shen-Chih^ORCID,Huang Po-Hsun,Gordts Philip L.S.M.^ORCID,Yuan Zu-Yi,Tsimikas Sotirios^ORCID,Shyy John Y.J.

Funder

National Institutes of Health

National Natural Science Foundation of China

National Key Research and Development Program grant

Key Project of Research and Development Plan of Shaanxi Province

Ministry of Science and Technology, Taiwan

Academic Senate, University of California, San Diego

Foundation Leducq

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/143812/files/pdf

Reference35 articles.

1. NARC-1/PCSK9 and Its Natural Mutants

2. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease

3. Statins UpregulatePCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

4. Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

5. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Coding RNA Involved in the Pathogenesis of Atherosclerosis—A Narrative Review;Diagnostics;2024-09-07

2. Overexpression of Igf2-derived Mir483 inhibits Igf1 expression and leads to developmental growth restriction and metabolic dysfunction in mice;Cell Reports;2024-09

3. MicroRNA-mediated Regulation of LDL Receptor: Biological and Pharmacological Implications;Current Medicinal Chemistry;2024-04

4. Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease;Acta Biomaterialia;2024-01

5. Emerging Assays for Risk Assessment;Clinical Lipidology;2024